4
The advent of low-cost sequencing of the human genome will revolutionize our understanding of health and disease. Personalized medicine seeks to use genetic variation to develop new diagnostic tests and treatments and to identify the sub-groups of patients for whom they will work best. Personalized medicine can also help determine which groups of patients are more prone to developing some diseases and, ideally, help with the selection of lifestyle changes and/or treat-ments that can delay onset of disease or reduce its impact. Personalized medicine is poised to transform healthcare over the next several de-cades, offering the possibility of improved health outcomes and making healthcare more cost-effective. With the price of sequencing a complete genome falling into the $1,000 range, stunning advances are sure to come over the next few years. It is likely that a detailed genome se-quence will soon be part of a routine medical history, allowing unprec-edented precision in diagnosis and treatment. The DNA and RNA signa-tures of both complex, common diseases and rare, elusive conditions will yield their secrets. This year, our conference focuses on the amazing technological challenges and advances of “next-generation sequenc-ing,” examining the very latest approaches and how they are leading to profound changes in our understanding of basic biological questions and more efficacious and cost effective therapies. Come witness the latest in transformational personalized medicine technologies.
Personalized Medicine at San Francisco State UniversityA star-studded cast of biotechnology, investment, academic, diagnostic, and nonprofit and corporate research leaders share their perspectives on how the evolving landscape of Personalized Medicine is changing medical care and preventive medicine.
Hosted by the Department of Biology, the conference drew more than 140 scientists, health professionals, educators, journalists, alumni and students for each of the past five years.
The Time is Now
6.0Personalized MedicineSouth San Francisco Conference Center
Conference Program At-A-Glance
2013 Conference 30 May
8.00 BreakfastMaster of Ceremonies: Matthew Gardner, Executive Producer, TechNation, & Former President, BayBio8.50 Introductory RemarksMichael A. Goldman, Ph.D., Professor & Chair, Department of Biology, SF State9.00 Opening KeynotePrecision Medicine in the Era of the $1000 GenomeKimberly J. Popovits, Chairman of the Board, Chief Executive Officer & President, Genomic Health9.45 KeynoteNext-Gen Sequencing & Personalized MedicineJorge Leon, Ph.D., President & CEO, Leomics Associates10.15 Break10:30 Brief RemarksLeslie Wong, President, San Francisco State University10.35 PanelNextGen TechnologiesModerator: Ken Hitchner, Vice President, Development Sciences Project Management, BioMarin Pharmaceutical IncChristos J. Petropoulos, Ph.D., Vice President of Research and Development, Monogram Biosciences/LabCorpJonas Korlach, Ph.D., Founder & CSO, Pacific BiosciencesFrank S. Ong, MD, Associate Director, Medical Affairs, Illumina, Inc.11.50 Lunch & Networking12:40 KeynoteMedical Informatics: Making the Most of the Sequence Data DelugeAtul Butte, M.D., Ph.D., Stanford University1:25 Keynote:Targeted Oncology TherapeuticsMark Sliwkowski, Ph.D., Distinguished Staff Scientist, Research Oncology, Genentech, Inc.2:10 Brief RemarksSheldon Axler, Ph.D., Dean, College of Science & Engineering, SF State2:15 PanelPublic Policy Impacting Personalized MedicineModerator: Kathryn Lowell, Executive Director, Government Affairs, BioMarin Pharmaceutical IncHank Greely, Professor of Law, Director, Center for Law and the Biosciences, Stanford UniversityMichael J. Shuster, Ph.D., Partner, Fenwick & West LLPPaul Sheives, JD, Director, Diagnostics and Personalized Medicine Policy, Biotechnology Industry Organization2:55 Break3:10 PanelRegional Investment in Personalized MedicineModerator: Andrew J. Copestake, CEO, Swedish Biomimetics 3000Stefan Johansson, CEO, Invest in Skane, Sweden “The dynamic development of Medicon Valley in the Scandinavian Bay Area”Michael Lappen, Economic Development Coordinator, City of South San Francisco4:10 Closing KeynoteDecoding Cancer Using Affinity ProteomicsCarl Borrebaeck Ph.D., Professor & Chair of Immunotechnology, Director, CREATE Health, Deputy Vice Chancellor, Lund University5:00 Closing RemarksKevin Mullin, California State Assemblymember, Chair, Select Committee on Biotechnology5:20 Reception & Student Poster Competition
Conference Organizing Team:
Arlene Essex Fiscal Analyst SF State College of Science & Engineering
Michael A. Goldman, Ph.D. Professor & Chair SF State Department of Biology Ken Hitchner Vice President,Development Sciences Project ManagementBioMarin Pharmaceutical IncMA Biology, SF State Dan Maher Sr. Vice President – Product Development BioMarin Pharmaceutical Inc BA Biology, SF State
Sally G. Pasion, Ph.D. Associate Professor SF State Department of Biology
John WulfPresidentNew Frontier Life Sciences Consulting MBA, SF State
Thank you to our 2013 SponsorsExecutive Partners
Partners
Sponsors
SupportersWatch for Personalized Medicine 7.0 in 2014!
Visit our web site or contact us for information about the conference or to be a sponsor.
http://personalizedmedicine.sfsu.edu
The Department of Biology at SF State University
Advancing global health & the biosphere
KENSON VENTURES, LLC
